WallStreetZenWallStreetZen

NASDAQ: RNA
Atrium Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RNA

Based on 1 analyst offering 12 month price targets for Atrium Therapeutics Inc

Min Forecast
$25.00+96.7%
Avg Forecast
$25.00+96.7%
Max Forecast
$25.00+96.7%

Should I buy or sell RNA stock?

Based on 1 analyst offering ratings for Atrium Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RNA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RNA as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their RNA stock forecasts and price targets.

RNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-11

1 of 1

Forecast return on equity

Is RNA forecast to generate an efficient return?

Company
-115.69%
Industry
69.66%
Market
163.77%
RNA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RNA forecast to generate an efficient return on assets?

Company
868.58%
Industry
31.79%
RNA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RNA earnings per share forecast

What is RNA's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$4.18
Avg 2 year Forecast
-$4.67
Avg 3 year Forecast
-$1.23

RNA revenue forecast

What is RNA's revenue in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$8.1M-56.6%
Avg 2 year Forecast
$8.1M-56.6%
RNA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RNA revenue growth forecast

How is RNA forecast to perform vs Biotechnology companies and vs the US market?

Company
-24.29%
Industry
38.93%
Market
13.99%
RNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AAPG$25.33$48.40+91.08%Strong Buy
AARD$3.94$14.83+276.47%Buy
ABUS$4.15$5.00+20.48%Strong Buy
ABVC$1.43N/AN/A
ABVX$126.14$145.00+14.95%Strong Buy
View Top Biotech Stocks

Atrium Therapeutics Stock Forecast FAQ

Is Atrium Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: RNA) stock is to Strong Buy RNA stock.

Out of 1 analyst, 1 (100%) are recommending RNA as a Strong Buy, 0 (0%) are recommending RNA as a Buy, 0 (0%) are recommending RNA as a Hold, 0 (0%) are recommending RNA as a Sell, and 0 (0%) are recommending RNA as a Strong Sell.

If you're new to stock investing, here's how to buy Atrium Therapeutics stock.

What is RNA's earnings growth forecast for 2026-2028?

(NASDAQ: RNA) Atrium Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.

Atrium Therapeutics's earnings in 2026 is -$49,501,000.On average, 2 Wall Street analysts forecast RNA's earnings for 2026 to be -$64,874,279, with the lowest RNA earnings forecast at -$62,947,320, and the highest RNA earnings forecast at -$67,443,557. On average, 2 Wall Street analysts forecast RNA's earnings for 2027 to be -$72,395,934, with the lowest RNA earnings forecast at -$70,245,560, and the highest RNA earnings forecast at -$75,263,100.

In 2028, RNA is forecast to generate -$19,066,342 in earnings, with the lowest earnings forecast at -$52,760,193 and the highest earnings forecast at $24,761,886.

What is RNA's revenue growth forecast for 2026-2027?

(NASDAQ: RNA) Atrium Therapeutics's forecast annual revenue growth rate of -24.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.99%.

Atrium Therapeutics's revenue in 2026 is $18,618,000.On average, 2 Wall Street analysts forecast RNA's revenue for 2026 to be $125,360,925, with the lowest RNA revenue forecast at $121,637,333, and the highest RNA revenue forecast at $130,325,714.

In 2027, RNA is forecast to generate $125,360,925 in revenue, with the lowest revenue forecast at $121,637,333 and the highest revenue forecast at $130,325,714.

What is RNA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RNA) forecast ROA is 868.58%, which is higher than the forecast US Biotechnology industry average of 31.79%.

What is RNA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year RNA price target, the average RNA price target is $25.00, with the highest RNA stock price forecast at $25.00 and the lowest RNA stock price forecast at $25.00.

The Wall Street analyst predicted that Atrium Therapeutics's share price could reach $25.00 by Mar 11, 2027. The average Atrium Therapeutics stock price prediction forecasts a potential upside of 96.7% from the current RNA share price of $12.71.

What is RNA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RNA) Atrium Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that RNA's EPS will be -$4.18 for 2026, with the lowest EPS forecast at -$4.06, and the highest EPS forecast at -$4.35. On average, analysts forecast that RNA's EPS will be -$4.67 for 2027, with the lowest EPS forecast at -$4.53, and the highest EPS forecast at -$4.85. In 2028, RNA's EPS is forecast to hit -$1.23 (min: -$3.40, max: $1.60).

What is RNA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RNA) forecast ROE is -115.69%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.